• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

OverT Bio Secures $16M to Optimize Cell Therapy for Solid Tumors

by Fred Pennic 05/06/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
OverT Bio Secures $16M to Optimize Cell Therapy for Solid Tumors

What You Should Know: 

– OverT Bio, a data-driven biotech company focused on unlocking the curative potential of cell therapies for solid tumors raises $16M in seed funding round. Co-led by ARTIS Ventures and Wing VC, the round saw participation from a distinguished group of investors including Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and the Cancer Research Institute.

– The investment will fuel the company’s mission to develop more durable and effective cell therapies, offering new hope for patients battling advanced cancers.

A Data-Driven Approach to Cell Therapy Innovation

Founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana, OverT has pioneered new pooled functional screening and synthetic genomics platforms (OverTarget™ and OverTCR™) to develop next-generation engineered immune cells. OverT Bio takes a unique approach to cell therapy, leveraging a patient’s own immune response to discover novel cancer targets. The company’s groundbreaking technology scans the entire human genome, identifying new avenues to equip cell therapies with enhanced capabilities to combat and destroy cancer cells.

OverT Bio’s Pioneering Technologies:

  • Massively Parallel Genetic Screening: This technology identifies the most effective genetic modifications to endow immune cells with potent anti-cancer properties.
  • Single-Cell Multiomics: This platform provides a comprehensive view of individual cells within the tumor microenvironment, revealing critical insights for therapy development.
  • Synthetic Biology Techniques: OverT Bio utilizes synthetic biology to engineer next-generation cell therapies with superior efficacy.

OverT Bio’s core platform represents a paradigm shift in cell therapy development. It systematically analyzes every gene in the human genome to discover the optimal genetic modifications for arming immune cells with the ability to recognize and eliminate cancer.

Strong Leadership and Scientific Foundation

OverT Bio boasts a seasoned leadership team with extensive expertise in cell therapy and immunology. Co-founder and CEO, Dr. Mat Legut, brings a proven track record of translating scientific discoveries into life-saving treatments. Co-founder, Dr. Neville Sanjana, is a renowned researcher at the New York Genome Center and NYU, and a pioneer in CRISPR technology and high-throughput functional genomics.

“Cell therapies have shown, at least in blood cancers, that we can aim to completely cure patients that have even the most advanced diseases rather than just prolong their survival,” said Dr. Mat Legut, co-founder and CEO of OverT. “With OverT’s ability to rapidly screen and engineer thousands of genes, we are building next-generation therapies to cure advanced cancers of the solid tissues.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |